Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haloperidol vs Olanzapine for Terminal Delirium
NCT04750395Phase 2Unknown
- Sponsor
- HCA Hospice Care
- Start
- Sep 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of haloperidol and olanzapine in delirium, sponsored by HCA Hospice Care. Primary endpoints: Memorial Delirium Assessment Scale at 72 hours and Richmond Agitation-Sedation Scale modified for palliative care at 72 hours. Status: unknown.
02
Drugs
haloperidololanzapine
03
Conditions
delirium
Beyond the preview
Go deeper on NCT04750395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750395.